Sugi Predict

Sugi Predict / Targets / PDPK1

PDPK1

3-phosphoinositide-dependent protein kinase 1 · O15530 · PDPK1 on Sugi Atlas →

126,321 patent compounds predicted against PDPK1, 83,856 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL84573 SCHEMBL84573 0.55 17/20
SCHEMBL84515 SCHEMBL84515 0.55 15/20
SCHEMBL91579 SCHEMBL91579 0.55 15/20
SCHEMBL18053 SCHEMBL18053 1.00 12/20
SCHEMBL18054 SCHEMBL18054 1.00 12/20
SCHEMBL19691 SCHEMBL19691 1.00 11/20
SCHEMBL19692 SCHEMBL19692 1.00 11/20
SCHEMBL20762 SCHEMBL20762 0.67 9/20
SCHEMBL20763 SCHEMBL20763 0.67 9/20
SCHEMBL25111 SCHEMBL25111 0.64 9/20
SCHEMBL152885 SCHEMBL152885 0.80 8/20
Celecoxib Celecoxib (SCHEMBL3708) 1.00 7/20
SCHEMBL18878 SCHEMBL18878 1.00 6/20
SCHEMBL20944 SCHEMBL20944 1.00 6/20
SCHEMBL20945 SCHEMBL20945 1.00 6/20
SCHEMBL106533 SCHEMBL106533 0.65 5/20
SCHEMBL25738 SCHEMBL25738 0.70 4/20
SCHEMBL21115 SCHEMBL21115 0.69 4/20
SCHEMBL21116 SCHEMBL21116 0.69 4/20
SCHEMBL22682 SCHEMBL22682 0.69 4/20

Clinical trials — most relevant to PDPK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI PHASE2COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDPK1 binder may also engage these)

ProteinNameSimilarity
RPS6KB1 Ribosomal protein S6 kinase beta-1 0.993 landscape →
Q8BSK8 — 0.992 Q8BSK8 →
O55173 — 0.992 O55173 →
Q6U1I9 — 0.992 Q6U1I9 →
Q6TJY3 — 0.992 Q6TJY3 →
Q91VB2 — 0.989 Q91VB2 →
Q9Z2A0 — 0.989 Q9Z2A0 →
Q6A1A2 — 0.988 Q6A1A2 →
RPS6KA5 Ribosomal protein S6 kinase alpha-5 0.988 landscape →
Q2LZZ7 — 0.988 Q2LZZ7 →
Q69Z98 — 0.987 Q69Z98 →
Q02111 — 0.987 Q02111 →
Q9WVC6 — 0.987 Q9WVC6 →
BRSK2 Serine/threonine-protein kinase BRSK2 0.987 landscape →
Q39030 — 0.987 Q39030 →
Q6GLY8 — 0.986 Q6GLY8 →
Q8C050 — 0.986 Q8C050 →
Q91821 — 0.986 Q91821 →
P67999 — 0.985 P67999 →
STK38 Serine/threonine-protein kinase 38 0.985 landscape →
Q7TPS0 — 0.985 Q7TPS0 →
A7MB74 — 0.985 A7MB74 →
Q09537 — 0.985 Q09537 →
P18654 — 0.985 P18654 →
Q9Z1M4 — 0.985 Q9Z1M4 →
Q06226 — 0.985 Q06226 →
RPS6KA3 Ribosomal protein S6 kinase alpha-3 0.984 landscape →
Q9JJX8 — 0.984 Q9JJX8 →
Q16975 — 0.984 Q16975 →
Q9WTQ0 — 0.984 Q9WTQ0 →